Mimedx Group Inc(MDXG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.13 | Insider Own | 21.58% | Shs Outstand | 145.9M | Perf Week | -0.77% |
| Market Cap | 0.57B | Forward P/E | 51.05 | EPS next Y | 182.16% | Insider Trans | - | Shs Float | 114.4M | Perf Month | -16.38% |
| Enterprise Value | 0.45B | PEG | - | EPS next Q | 0.02 | Inst Own | 57.9% | Short Float | 8.1% | Perf Quarter | -9.13% |
| Income | -0.02B | P/S | 1.86 | EPS this Y | -128.91% | Inst Trans | -0.27% | Short Ratio | 6.73 | Perf Half Y | 5.43% |
| Sales | 0.30B | P/B | 2.68 | EPS next 5Y | -17.96% | ROA | -6.58% | Short Interest | 9.26M | Perf YTD | -42.69% |
| Book/sh | 1.45 | P/C | 4.69 | EPS past 3/5Y | - | ROE | -8.53% | 52W High | -51.32% ($7.97) | Perf Year | -47.57% |
| Cash/sh | 0.83 | P/FCF | 29.83 | Sales past 3/5Y | 16.05% 11.02% | ROIC | -9.09% | 52W Low | 28.26% ($3.03) | Perf 3Y | -38.61% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -147.2% | Gross Margin | 76.95% | Volatility(W/M) | 5.43% 4.97% | Perf 5Y | -43.36% |
| Dividend TTM | - | EV/Sales | 1.47 | Sales Y/Y TTM | -22.8% | Oper. Margin | -8.28% | ATR (14) | 0.21 | Perf 10Y | -55.81% |
| Dividend Ex-Date | - | Quick Ratio | 3.84 | EPS Q/Q | -153.17% | Profit Margin | -6.32% | RSI (14) | 32.87 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.35 | Sales Q/Q | -45.23% | SMA20 | -9.91% ($4.31) | Beta | 1.15 | Target Price | $7 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/10/28 | SMA50 | -13.52% ($4.49) | Rel Volume | 1.54 | Prev Close | $3.97 |
| Employees | 808 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -20100% -9.16% | SMA200 | -9.17% ($4.27) | Avg Volume(3M) | 1.38M | Price | $3.88 |
| IPO | 2007/8/22 | Option/Short | Yes/Yes | Trades | 6520 | Volume | 2,124,744 | Change | -2.27% |
🩹 MiMedx Group (MDXG) is a US healthcare company that develops and sells regenerative biomaterials and allografts derived from human placental tissue. It supplies patented regenerative biologics products such as EpiFix and AmnioFix for the treatment of chronic wounds, surgery, and sports medicine/orthopedics, and has established itself as a specialist in the advanced wound care market.
Over the past 1 year, on the lower side
51% below its 1-year high.
Traded more than usual. That is 154% of its average volume.
MDXG has a sound balance sheet but weak earning power
Of every $100 in sales, $8.28 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -128.9% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $186. Peers typically go for $1,268. Compared with its own 3-year average, it is 291% pricier now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -43.4%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 57.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #204 of 597 in the industry
Based on market cap of $566M.
GERN#203 Geron Corp $575M PER - MDXG#204 Mimedx Group Inc $566M PER - 
ANL#205 Adlai Nortye Group Ltd ADR $561M PER - 
STTK#206 Shattuck Labs Inc $558M PER - 
ENTX#207 Entera Bio Ltd $557M PER - 
FAQ
What kind of company is MDXG?
MDXG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MDXG?
The market cap of MDXG is approximately $566M, ranking 3,038 within its sector.
What is the 52-week high and low for MDXG?
MDXG has recorded a 52-week high of $7.97 and a low of $3.03.
